Construction Of 7 Pharmaceutical Production Plants: Turk IIac And Interglobe IEG Join Forces

Listed on the Istanbul Stock Exchange since 2021, TURK Ilaç is one of the largest Turkish companies specializing in the production of pharmaceutical products, including vaccines and serums.
Between 2022 and 2024, TURK Ilaç aims to establish seven integrated production plants in Africa, similar to those it has successfully completed in Turkey. TURK Ilaç factories will be installed in Angola, Benin, Congo Brazzaville, Guinea, Mauritania, Nigeria and Senegal, following agreements with the respective governments of these countries.

Main supplier of the national vaccine immunization program, TURK Ilaç now intends to bring its experience, expertise and know-how to Africa to contribute to the emergence of an African pharmaceutical industry. “The development of these seven production units across Africa is of paramount importance for the sustainable development, not only of Africa but also of the global economy as a whole,” said Mehmet Berat Battal, President by TURK Ilac.

TURK Ilaç also plans to strengthen and expand its footprint in a single trading bloc to create unique and shared value for its investors and the African continent. In addition to the investments of Turkish medicine in the pharmaceutical sector in Africa, encouraging steps have been taken in the field of the production of sub-industries, an indispensable branch of the field. By calling on all the industrial capacities of the companies of the TURK Ilaç group, which depend on BATTAL Holding in its country, it has succeeded in carrying out integrated productions at low cost, without compromising on quality.

TURK Ilaç, which has a solid financial structure, said that the company would not hesitate to take action in this regard and was happy to be supported both by the authorities of the countries in which the investments will be made, by Afrexim and other related funds. Following the meetings held with the competent authorities of the countries where the investment will be made, TURK Ilaç received very good feedback on the purchase guarantee and the allocation of spaces in order to encourage local production.

This ambitious action plan and expansion project was drawn up and signed following the Turkey-Africa summit by Interglobe, an American company specializing in finding investment opportunities in Africa for foreign companies. TURK Ilaç’s action plan for the continent focuses on four key areas: investing in the pharmaceutical sector in Africa, to ensure the health and well-being of all; the transfer of advanced technologies and best practices in Africa; promotion of women’s employment; research and development.

This plan is in line with the agreements signed between InterGlobe and the African Continental Free Trade Area (ZLECAF) aimed at developing the local pharmaceutical industry, creating jobs, attracting foreign investment and facilitating technology transfer in Africa.
During the signing of the action plan, the executive chairman of the Interglobe IEG group, Bunmi Jinadu, said: “It is quite worrying that trade between African countries represents only 18% of world trade. We firmly believe that supporting the development of a sustainable pharmaceutical industry in Africa is a powerful contribution to achieving the Sustainable Development Goals. The AFCFTA is an essential tool that will accelerate and strengthen trade between African countries and between Africa and other continents and will serve as a catalyst for sustainable development in Africa for future generations. »

The COVID-19 pandemic has shown how supply chain disruptions can affect production runs and blocks around the world. In addition, the slowdown in the production of medicines and the increase in prices have had a global impact on the supply of pharmaceutical products, in particular for Africa, an importer of medical and pharmaceutical products.